Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Neurocrine Biosciences announced it will present research on Prader-Willi syndrome and real-world experience with VYKAT XR at the Foundation for Prader-Willi Research 2026 Annual Research Symposium, Oct. 7-10 in Philadelphia. Presentations include the PWS-VISTA and BRAVE-PWS observational studies plus an integrated analysis of adverse events of special interest during VYKAT XR treatment.
Key figures
- Conference
- Foundation for Prader-Willi Research 2026 Annual Research Symposium & Family Conference
- Conference dates
- Oct. 7-10, 2026
- Vykat xr fda approval date
- March 26, 2025
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.